Tomahawk, WI 10/08/2014 (Basicsmedia) – The current Ebola epidemic which is believed to be the worst in history has pulled pharmaceutical companies together in the attempt of trying to find the ultimate solution in terms of cures and vaccines. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and other stocks in the space have experienced impressive run-ups in the market as they continue to report favorable news with ongoing trials.

None of the pharmaceutical companies according to CNBC’s Melisa Lee is poised to produce hundreds of doses due to financial constraints but still continue to record impressive run in terms of stock prices.

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) just like other pharmaceutical companies is not an Ebola pure play but has interests in Cancer and Hepatitis B according to CNBC’s Meg Tirrell. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)’s Ebola drug TKM-Ebola is currently being administered in what is known as expedited trial on patients in the U.S.

“[…] Tekmira has been getting a lot of attention because it was given to Dr. Richard Sacra who was treated in Nebraska and to a few other patients. This drug works by RNA interference, which essentially does work to silence some of the problematic proteins that help with replicating of the virus,” said Tirrell.

Chimerix Inc. (NASDAQ:CMRX) is another company whose drug Brincindofovir is being administered on an infected patient in Dallas. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is also tapping into the space having developed its own drug although it has not yet been administered on humans like Tekmira’s.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), on the other hand, continues to receive the least attention as analyst believe it could enjoy a breakthrough with its drug for hereditary angioedema and not Ebola. Analysts believe that the drug could present the company with a $1 billion sales opportunity.

“It is important to note that all of these companies are working on other things other than Ebola but it is Ebola that has been driving their stock the last couple of months,” said Mrs. Tirrell.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.